معرفی
Dr. Daryl Klein is an Associate Professor of Pharmacology at Yale School of Medicine, affiliated with the Yale Cancer Biology Institute, Yale Cancer Center, and the Program in Translational Biomedicine. He holds a MD and PhD from the University of Pennsylvania (2009, 2008) and a BA in Biology (1999). His research focuses on molecular mechanisms of cancer metastasis, particularly signal integration across biological membranes. He investigates how signaling 'codes' in receptor structures drive disease progression and designs synthetic interventions to override these pathways. His interdisciplinary work combines biophysics, virology, and high-throughput screening to target metastatic pathways and enhance immune responses.
Recent research highlights include structural studies of Isthmin-1 (2025), interactions between RTKs and GPCRs in Drosophila (2025), and GABAA receptor signaling in ERK activation (2024). He leads a lab at Yale West Campus Advanced Biosciences Center and has secured grants like a $10.5M NIH award for membrane protein research (2023). Collaborations with experts like Mark Lemmon and Steve Stayrook drive his work. Current projects aim to develop CAR-T cell therapies for neuroblastoma (ALK inhibition synergy) and structural biology of receptor systems.
His lab hosts a vibrant research environment with over 20 publications in high-impact journals like Nature Communications and Molecular Cell. Future directions include synthetic biology approaches to reprogram cancer signaling circuits and translating findings into clinical therapeutics.
